Banach Maciej, Mikhailidis Dimitri P
Department of Hypertension, WAM University Hospital in Lodz, Medical University of Lodz (MUL), 113 Zeromskiego Street, Lodz 90-549, Poland; Polish Mother's Memorial Hospital Research Institute (PMMHRI), 281/289 Rzgowska Street, Lodz 93-338, Poland; Cardiovascular Research Centre, University of Zielona Gora, 28 Zyty Street, Zielona Gora 65-046, Poland.
Department of Clinical Biochemistry, Royal Free Campus, University College London Medical School, University College London (UCL), Pond Street, London NW3 2QG, UK.
Cardiol Clin. 2018 May;36(2):225-231. doi: 10.1016/j.ccl.2017.12.004. Epub 2018 Feb 21.
Statin intolerance is the inability to tolerate a dose of statin required to sufficiently reduce cardiovascular risk. With the five-step approach, more than 90% of these patients might be treated with statins. The principal approaches are to try not to discontinue statin therapy and to treat these patients as effectively as possible. New therapies with the proprotein convertase subtilisin-kexin type 9 inhibitors and bempedoic acid might be an effective response to these needs. In case of lack of achieved goal of the therapy nutraceuticals with confirmed low-density lipoprotein cholesterol reduction properties may be considered as a part of the lipid-lowering combination therapy.
他汀不耐受是指无法耐受足够降低心血管风险所需剂量的他汀类药物。采用五步疗法，超过90%的此类患者可能接受他汀类药物治疗。主要方法是尽量不中断他汀治疗，并尽可能有效地治疗这些患者。前蛋白转化酶枯草溶菌素9型抑制剂和贝派地酸等新疗法可能有效满足这些需求。如果治疗未达到目标，具有已证实的降低低密度脂蛋白胆固醇特性的营养保健品可被视为降脂联合治疗的一部分。
